More recently, multiple clinical studies have revealed that PI3K inhibitors are active in PIK3CA mutant HR+ breast cancer, including two studies with the pan-class I PI3K inhibitor buparlisib in BELLE-2 and BELLE-3 [[81], [82], [83]]. This evidence concerns the gene PIK3CA and breast cancer.